INVESTOR DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc.
March 11 2016 - 9:35PM
Business Wire
Law Office of Brodsky & Smith, LLC announces an
investigation of Esperion Therapeutics, Inc. (“Esperion” or the
“Company”) (Nasdaq: ESPR) for potential violations of federal
securities laws and breaches of the Esperion Board’s fiduciary
duties.
Click here to learn more
http://brodsky-smith.com/1042-espr-esperion-therapeutics-inc.html,
or call: 877-534-2590. There is no cost or obligation to you.
The investigation concerns a securities class action lawsuit
commenced in the United States District Court for the Eastern
District of Michigan. The complaint alleges that the Defendants
made false and misleading statements including failing to disclose
that there was no clear path to approval for ETC-1002, and that the
FDA had encouraged the Company to initiate a cardiovascular
outcomes trial. According to the complaint, following the September
28, 2015 disclosure of these facts, shares of Esperion stock
declined significantly.
If you purchased shares of Esperion common stock between August
18, 2015 and September 28, 2015, and wish to discuss the
investigation, or if you have any questions, you may e-mail or call
the law office of Brodsky & Smith, LLC by March 14, 2016, who
will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L. Brodsky, Esquire or Evan J.
Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com, by visiting
http://brodsky-smith.com/1042-espr-esperion-therapeutics-inc.html,
or calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive
expertise representing shareholders throughout the nation in
securities and class action lawsuits. The attorneys at Brodsky
& Smith have been appointed by numerous courts throughout the
country to serve as lead counsel in class actions and successfully
recovered millions of dollars for our clients and shareholders.
Attorney advertising. Prior results do not guarantee a similar
outcome.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160311005832/en/
Brodsky & Smith, LLCJason L. Brodsky, EsquireEvan J. Smith,
Esquire877-LEGAL-90investorrelations@brodsky-smith.comhttp://brodsky-smith.com/1042-espr-esperion-therapeutics-inc.html
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024